Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Cue Biopharma Inc.

Cue Biopharma ($CUE) announced an update on their ongoing clinical study. Cue Biopharma’s HPV-Linked Head and Neck Cancer Study Reaches Key Milesto...

Cue Biopharma’s CUE-101 Trial Hits Completion: What It Means for Cancer Investors

Chengdu Putian Telecommunications Cable Co., Ltd. Class H ( ($HK:1202) ) has issued an update. Chengdu SIWI Science and Technology Company Limited ...

Chengdu SIWI Clarifies Scope of Connected Transactions in Optical Communications Deals

Cuentas ( ($CUEN) ) has provided an update. On January 7, 2026, Cuentas, Inc. entered into a Limited Liability Company Agreement with Tummo Road LL...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CUE	$0.38	+4.17%	994.59K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CUE	$0.38	+4.2%	994.59K
3
4
5
6

CUE

CUE

Get Cue Biopharma Inc. Data in Excel

Get Cue Biopharma Inc. Data in Excel